Epilepsy affects about 50 million people worldwide, making it one of the most common neurological disorders. In India, nearly ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

This article is authored by Dr Amit Kumar Agarwal, senior consultant, neurosciences, neurology and stroke medicine, Amrita ...

With NIH support, biomedical engineer Sri Sarma develops neurotechnologies to improve understanding and treatment of epilepsy ...

They took this step after three different drugs failed to stop her seizures. Now, a new breakthrough could mean that even ...

The drug, called tofacitinib, also restores short-term and working memory lost to epilepsy in the mice and reduces ...

Epilepsy is a seizure disorder that is described by the International League Against Epilepsy as two unprovoked seizures that ...

A new technique involving ultra-powerful MRI scanners could help doctors identify tiny differences in the brains of people ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

A real-world study supports cenobamate as an effective option for patients with drug-resistant epilepsy even after multiple ...